IPO - Predictive Oncology Inc.

Form Type: S-1

Filing Date: 2025-07-18

Corporate Action: Ipo

Type: New

Accession Number: 000117184325004561

Filing Summary: Predictive Oncology Inc., a Delaware-based company focused on applying AI to discover and develop cancer therapies, filed the Form S-1 registration statement with the SEC on July 18, 2025. This registration statements pertains to the resale of up to 1,921,706 shares of common stock by YA II PN, LTD, who is acting as the selling stockholder. The shares to be offered include both already issued shares and those that may be issued in the future as part of a standby equity purchase agreement (SEPA) established on July 1, 2025. The company disclosed it will not receive proceeds from the sale of the shares by the selling stockholder but may acquire gross proceeds of up to $10 million from future sales. The document highlights the risks associated with investing in their common stock, including a recent notice of delisting from Nasdaq due to not meeting minimum stockholders’ equity requirements. The company is currently working to regain compliance and has made plans to appeal this decision, with potential strategic adjustments including possible mergers or stock splits. Notably, Predictive Oncology also reported on past acquisition negotiations with Renovaro, which have since been terminated, along with ongoing litigation associated with those discussions.